Introduction: Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The lipid changes associated with diabetes mellitus are attributed to increased free fatty acid flux secondary to insulin resistance. Materials and Methods: This is prospective, comparative, open label, randomized and parallel group. The subjects enrolled for this study were selected from the Out-Patient Department of Medicine collaboration with Department of Pharmacology, Tertiary care teaching hospital over a period of month. Newly diagnosed 90 cases of patients of Type II Diabetes Mellitus well controlled on oral hypoglycemic drugs were randomly divided into 3 groups of 30 each. Group A was received Rosuvastain 10 mg O.D for 3 months, Group B: Simvastatin 10 mg O.D and Group C was received Atrovastatin 10 mg O.D. Results: In Group ‘A’ the mean difference of Total Cholesterol between baseline versus after 6 months was 82.37 mg/dl, 64.92 mg/dl and 52.23 mg/dl in Group B and Group C respectively. The mean difference of Triglycerides between baseline versus after 6 months was 65.04 mg/dl in Group A, 39.99 mg/dl in Group B and 37.04 mg/dl in Group C. The mean difference of HDL between baseline versus after 6 months was 10.04 mg/dl in Group A, 10.26 mg/dl in Group B and 9.13 mg/dl in Group C. The mean difference of LDL between baseline versus after 6 months was 79.4 mg/dl in Group A, 67.6 mg/dl in Group B and 33.82 mg/dl in Group C. The mean difference of VLDL between baseline versus after 6 months was 13.01 mg/dl in Group A, 7.58 mg/dl in Group B and 7.41 mg/dl in Group C. Conclusion: Finally using Rosuvastatin seems high for the patients but the result obtained by reducing the lipid parameters by given therapy is beneficial to the patients in long term control of lipid profile and thus helps in the overall reduction of morbidity and mortality in patients with type 2 diabetes mellitus with dyslipidaemia.